Q&A with Thetis Advisors

Dr. Charles Serhan, Professor of Medicine at Harvard Medical School; Dr. John Parkinson, Senior R&D Director at Thetis; Dr. Chris Takimoto, CMO at IGM Biosciences; Dr. Wayne Klohs, Chair of Thetis Cancer Advisory Board; Dr. Dipak Panigrahy, Professor of Medicine at Harvard Medical School; Dr. Sui Huang, Professor of Medicine at the Institute for Systems […]

Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class Resolvin Oral Therapy for Crohn’s Disease

RIDGEFIELD, CT AND NEW YORK, NY – (April 5, 2022) – Thetis Pharmaceuticals (“Thetis”), a pioneering therapeutics biotechnology company developing a first-in-class small molecule (TP-317) as a potential oral first-line therapy for treatment of Crohn’s disease, has secured $4.2 million in non-dilutive financing from The Leona M. and Harry B. Helmsley Charitable Trust. Structured as […]

Chris Takimoto, MD, PhD, Physician-Scientist and Oncology Drug Developer, Joins Thetis Pharmaceuticals Scientific Advisory Board

RIDGEFIELD, CT – (December 2, 2021) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing immunoresolving myeloid agonists to treat cancer and autoimmune diseases, announced today that Dr. Chris Takimoto has joined its Scientific Advisory Board. Dr. Takimoto is a physician scientist with expertise in cancer drug development.  Gary Mathias, Chief Executive Officer of Thetis, […]

Sui Huang, MD, PhD, Pioneering Cancer Biology Researcher, Joins Thetis Pharmaceuticals Scientific Advisory Board

RIDGEFIELD, CT – (October 13, 2021) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing Resolvin-based therapies to treat cancer and autoimmune diseases, announced today that Dr. Sui Huang has joined its Scientific Advisory Board. Dr. Huang is a molecular and cellular biologist with expertise in systems biology of cancer progression and inflammation. Gary Mathias, […]